DE69333710D1 - Genvarianten des angiotensinogens und veranlagung zum bluthochdruck - Google Patents

Genvarianten des angiotensinogens und veranlagung zum bluthochdruck

Info

Publication number
DE69333710D1
DE69333710D1 DE69333710T DE69333710T DE69333710D1 DE 69333710 D1 DE69333710 D1 DE 69333710D1 DE 69333710 T DE69333710 T DE 69333710T DE 69333710 T DE69333710 T DE 69333710T DE 69333710 D1 DE69333710 D1 DE 69333710D1
Authority
DE
Germany
Prior art keywords
angiotin
sinogen
geni
variants
high pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333710T
Other languages
English (en)
Inventor
Jean-Marc Lalouel
Xavier Jeunemaitre
P Lifton
Florent Soubrier
Youri Kotelevtsev
Pierre Corvol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
University of Utah Research Foundation UURF
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, University of Utah Research Foundation UURF filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of DE69333710D1 publication Critical patent/DE69333710D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
DE69333710T 1992-09-30 1993-09-29 Genvarianten des angiotensinogens und veranlagung zum bluthochdruck Expired - Lifetime DE69333710D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/952,442 US5374525A (en) 1992-09-30 1992-09-30 Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
PCT/US1993/009136 WO1994008048A1 (en) 1992-09-30 1993-09-29 Angiotensinogen gene variants and predisposition to hypertension

Publications (1)

Publication Number Publication Date
DE69333710D1 true DE69333710D1 (de) 2004-12-30

Family

ID=25492918

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333710T Expired - Lifetime DE69333710D1 (de) 1992-09-30 1993-09-29 Genvarianten des angiotensinogens und veranlagung zum bluthochdruck

Country Status (10)

Country Link
US (5) US5374525A (de)
EP (1) EP0665898B1 (de)
JP (1) JP3159708B2 (de)
KR (1) KR950704507A (de)
AT (1) ATE283372T1 (de)
AU (1) AU670990B2 (de)
CA (1) CA2145415A1 (de)
DE (1) DE69333710D1 (de)
NZ (1) NZ259092A (de)
WO (1) WO1994008048A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374525A (en) * 1992-09-30 1994-12-20 University Of Utah Research Foundation Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension
US6153386A (en) * 1992-09-30 2000-11-28 University Of Utah Research Foundation Method to determine predisposition to hypertension
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
DE19613606C1 (de) 1996-04-04 1997-04-30 Progen Biotechnik Gmbh Gen für Hypertonie
US6114118A (en) * 1996-09-20 2000-09-05 Texas A&M University System Method of identification of animals resistant or susceptible to disease such as ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis
US6197505B1 (en) * 1997-04-04 2001-03-06 Pyrosequencing Ab Methods for assessing cardiovascular status and compositions for use thereof
US20020123467A1 (en) * 1999-09-02 2002-09-05 Institut Pasteur Therapeutic composition comprising the KAL protein and use of the KAL protein for the treatment of retinal, renal, neuronal and neural injury
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
DE69930726T2 (de) * 1998-01-12 2007-01-25 Massachusetts Institute Of Technology, Cambridge Verfahren und vorrichtung zur mikrotestdurchführung
US6893877B2 (en) 1998-01-12 2005-05-17 Massachusetts Institute Of Technology Methods for screening substances in a microwell array
US6525185B1 (en) * 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
CA2342921A1 (en) 1998-09-04 2000-03-16 University Of Utah Research Foundation Drug screening and diagnosis based on paracrine tubular renin-angiotensin system
JP2002529718A (ja) * 1998-11-10 2002-09-10 ジェンセット 検出可能な形質と結合された遺伝子を含むゲノム領域を同定するための方法、ソフトウエアおよび装置
EP1165235B1 (de) 1999-03-19 2011-09-28 Life Technologies Corporation Methode zum sichten von mutierten zellen
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
US6902888B1 (en) 1999-05-21 2005-06-07 Myriad Genetics, Inc. Diabetes gene
US20020119448A1 (en) * 1999-06-23 2002-08-29 Joseph A. Sorge Methods of enriching for and identifying polymorphisms
US6177252B1 (en) * 1999-08-27 2001-01-23 University Of Utah Research Foundation Method to determine predisposition to hypertension
US7076437B1 (en) 1999-10-29 2006-07-11 Victor Levy Process for consumer-directed diagnostic and health care information
US20020151040A1 (en) 2000-02-18 2002-10-17 Matthew O' Keefe Apparatus and methods for parallel processing of microvolume liquid reactions
CA2400644C (en) * 2000-02-18 2009-07-14 Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for parallel processing of micro-volume liquid reactions
US20040248092A1 (en) * 2000-05-26 2004-12-09 Vance Jeffrey M Methods of screening for parkinsons's disease
WO2002002000A2 (en) * 2000-06-30 2002-01-10 Duke University Methods of screening for alzheimer's disease
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US20030219776A1 (en) * 2001-12-18 2003-11-27 Jean-Marc Lalouel Molecular variants, haplotypes and linkage disequilibrium within the human angiotensinogen gene
EP1481066A2 (de) * 2002-02-27 2004-12-01 Bayer HealthCare AG Einzelnukleotidpolymorphismen zur vorhersage negativer arzneistoffreaktionen und der medikationswirksamkeit
US20040014109A1 (en) * 2002-05-23 2004-01-22 Pericak-Vance Margaret A. Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases
WO2004005534A2 (en) * 2002-07-08 2004-01-15 Duke University Screening for alzheimer's disease
US8277753B2 (en) 2002-08-23 2012-10-02 Life Technologies Corporation Microfluidic transfer pin
EP1608952B1 (de) 2002-12-20 2016-08-10 Life Technologies Corporation Assay vorrichtung und verfahren unter verwendung von mikrofluiden matrixstrukturen
US20060246437A1 (en) * 2003-07-11 2006-11-02 Pericak-Vance Margaret A Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20050191652A1 (en) * 2003-11-03 2005-09-01 Vance Jeffery M. Identification of genetic forms of a gene that leads to high risk for parkinson disease
CA2559171A1 (en) 2004-03-12 2005-09-29 Biotrove, Inc. Nanoliter array loading
US20060105453A1 (en) 2004-09-09 2006-05-18 Brenan Colin J Coating process for microfluidic sample arrays
US7790390B2 (en) * 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) * 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
WO2006069592A2 (en) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for diagnosing an/or predicting preeclampsia and/or related disorders
US20070148661A1 (en) * 2005-07-19 2007-06-28 Duke University LSAMP Gene Associated With Cardiovascular Disease
JP2007075015A (ja) * 2005-09-14 2007-03-29 Tokai Univ 高血圧症の検査用マーカー遺伝子
WO2010104646A1 (en) * 2009-03-09 2010-09-16 Scott and White Memorial Hospital Method of testing a patient for hypertension and related method of treatment and test kit
JP6811094B2 (ja) 2014-05-22 2021-01-13 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． アンジオテンシノーゲン（ＡＧＴ）ｉＲＮＡ組成物およびその使用
CN108588211B (zh) * 2018-05-02 2020-05-19 青岛泱深生物医药有限公司 一种子痫前期的生物标志物及其应用
TW202016304A (zh) 2018-05-14 2020-05-01 美商阿尼拉製藥公司 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
MX2022005692A (es) 2019-11-13 2022-06-08 Alnylam Pharmaceuticals Inc Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
KR20240026203A (ko) 2021-06-30 2024-02-27 알닐람 파마슈티칼스 인코포레이티드 안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
TW202337474A (zh) 2021-08-04 2023-10-01 美商艾拉倫製藥股份有限公司 用於緘默血管收縮素原（ＡＧＴ）的ｉＲＮＡ組成物及方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153386A (en) * 1992-09-30 2000-11-28 University Of Utah Research Foundation Method to determine predisposition to hypertension
US5374525A (en) * 1992-09-30 1994-12-20 University Of Utah Research Foundation Methods to determine predisposition to hypertension and association of variant angiotensinogen gene and hypertension

Also Published As

Publication number Publication date
US6165727A (en) 2000-12-26
US5763168A (en) 1998-06-09
KR950704507A (ko) 1995-11-20
NZ259092A (en) 1996-05-28
EP0665898A1 (de) 1995-08-09
WO1994008048A1 (en) 1994-04-14
EP0665898B1 (de) 2004-11-24
US5374525A (en) 1994-12-20
EP0665898A4 (de) 1998-08-05
JPH08505043A (ja) 1996-06-04
US5998145A (en) 1999-12-07
CA2145415A1 (en) 1994-04-14
US5589584A (en) 1996-12-31
ATE283372T1 (de) 2004-12-15
JP3159708B2 (ja) 2001-04-23
AU670990B2 (en) 1996-08-08
AU5725094A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
DE69333710D1 (de) Genvarianten des angiotensinogens und veranlagung zum bluthochdruck
DE3788691D1 (de) Verhütung von Fusariumkrankheiten und Mikroorganismen dafür.
ATA260087A (de) Kombination von angiotensin-converting-enzyme- hemmern mit calciumantagonisten sowie ein erzeugnis, das diese enthält, zur anwendung bei der behandlung des bluthochdrucks
DE69729646D1 (de) Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv
DK0668751T3 (da) Fikstur til et dentalimplantatsystem
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
TR199802694T2 (xx) IL-8 resept�r kar��tlar�
DE69739951D1 (de) Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
ID16044A (id) Pemurnian asam akrilik dan asam metakrilik
ES2154252T1 (es) Inhibicion de la quinasa p38 utilizando difenil-ureas simetricas y asimetricas.
DE69526206T2 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
DE69323019D1 (de) Verbesserter Nachweis von Mikroorganismen
DE69627153T2 (de) Zusammensetzungen zur erzielung von analgesie und zur hemmung der progression neuropathischer schmerzerkrankungen
HUP9802091A2 (hu) Idegátültetés pluripotens neuroepiteliális sejtek alkalmazásával
MX9702035A (es) Inhibidores de 5-alfa reductasa.
DE69633985D1 (de) Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid
DE69022373D1 (de) Wiedergewinnung von tert.-Butyl-hydroperoxid und von tert.-Butyl-Alkohol.
DE3686019T2 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
IT8622548A0 (it) Procedimento d'epurazione e di deodorizzazione di gas e installazione per la messa in opera di questo procedimento.
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
FR2710839B1 (fr) Composition cosmétique et méthode de traitement esthétique s'opposant au vieillissement de la peau.
CA2090738A1 (en) Use of PAF
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
DE69623325D1 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
DE68916377D1 (de) Reinigung von tertiären Hydroperoxiden die primäre und sekundäre Hydroperoxid-Verunreinigungen enthalten.

Legal Events

Date Code Title Description
8332 No legal effect for de